FDA finds Capricor's Duchenne stem cell therapy failed to meet Phase 3 goals, contradicting company claims

The U.S. Food and Drug Administration announced that the stem cell treatment from Capricor Therapeutics did not achieve the primary objectives in its Phase 3 trial for Duchenne muscular dystrophy. The agency’s assessment directly challenges the company’s earlier statements about the study’s success.

Capricor had reported in December that its drug, deramiocel, met both primary and secondary endpoints in a large, randomized trial. Those claims suggested a breakthrough for a disease with few effective options.

The FDA’s finding highlights a gap between the company’s public claims and the regulator’s evaluation, raising questions about the data presented and the path forward for the therapy.

For investors and clinicians following Duchenne research, the setback underscores the uncertainty that still surrounds advanced cell‑based approaches and may affect Capricor’s upcoming development plans.